MA46180A - Analogues de l'amyline - Google Patents

Analogues de l'amyline

Info

Publication number
MA46180A
MA46180A MA046180A MA46180A MA46180A MA 46180 A MA46180 A MA 46180A MA 046180 A MA046180 A MA 046180A MA 46180 A MA46180 A MA 46180A MA 46180 A MA46180 A MA 46180A
Authority
MA
Morocco
Prior art keywords
amyline
analogues
Prior art date
Application number
MA046180A
Other languages
English (en)
Inventor
Giacomo Fossati
Lise Giehm
Dieter Wolfgang Hamprecht
Alexander Heim-Riether
Jesper Mosolff Mathiesen
Henrik Kofoed Munch
Jesper Skodborg VILLADSEN
Original Assignee
Boehringer Ingelheim Int
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Zealand Pharma As filed Critical Boehringer Ingelheim Int
Publication of MA46180A publication Critical patent/MA46180A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
MA046180A 2016-09-09 2017-09-11 Analogues de l'amyline MA46180A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16188024 2016-09-09

Publications (1)

Publication Number Publication Date
MA46180A true MA46180A (fr) 2021-03-24

Family

ID=56990230

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046180A MA46180A (fr) 2016-09-09 2017-09-11 Analogues de l'amyline

Country Status (26)

Country Link
US (5) US10071140B2 (fr)
EP (4) EP4736945A2 (fr)
JP (1) JP7064103B2 (fr)
KR (1) KR102498393B1 (fr)
CN (1) CN109863168B (fr)
AR (1) AR109514A1 (fr)
AU (1) AU2017322277B2 (fr)
BR (1) BR112019004534A2 (fr)
CA (1) CA3035958A1 (fr)
CL (1) CL2019000575A1 (fr)
CO (1) CO2019002159A2 (fr)
DK (1) DK3510044T3 (fr)
EA (1) EA201990360A1 (fr)
ES (1) ES2901386T3 (fr)
IL (1) IL264864B2 (fr)
MA (1) MA46180A (fr)
MX (1) MX2019002599A (fr)
MY (1) MY197024A (fr)
PE (2) PE20190963A1 (fr)
PH (1) PH12019500474B1 (fr)
SA (1) SA519401239B1 (fr)
SG (1) SG11201901423XA (fr)
TW (1) TWI784968B (fr)
UA (1) UA123369C2 (fr)
WO (1) WO2018046719A1 (fr)
ZA (1) ZA201901253B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017019378A2 (pt) * 2015-03-18 2019-02-19 Zealand Pharma A/S análogos de amilina
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
AR116632A1 (es) 2018-10-11 2021-05-26 Intarcia Therapeutics Inc Polipéptidos análogos de la amilina humana y sus métodos de uso
CR20220206A (es) 2019-11-11 2022-06-16 Boehringer Ingelheim Int Agonistas del receptor npy2
JP7661478B2 (ja) 2020-08-07 2025-04-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性ｎｐｙ２受容体アゴニスト
TWI815327B (zh) 2021-03-03 2023-09-11 美商美國禮來大藥廠 長效澱粉素受體促效劑及其用途
EP4144362A1 (fr) 2021-09-06 2023-03-08 Adocia Compositions comprenant des hormones à brève durée d'action pour traiter ou prévenir l'obésité et pompes comprenant ladite composition
WO2022248419A2 (fr) 2021-05-22 2022-12-01 Adocia Compositions comprenant des hormones à action courte pour le traitement ou la prévention de l'obésité et pompes comprenant ladite composition
EP4129324A1 (fr) 2021-08-02 2023-02-08 Adocia Compositions comprenant au moins un agoniste au récepteur de l'amyline et un agoniste du récepteur glp-1
TW202346323A (zh) 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽
CA3257452A1 (fr) * 2022-05-27 2025-04-15 Hangzhou Sciwind Biosciences Co., Ltd. Analogue d'amyline humaine, dérivé et utilisation de celui-ci
TWI880227B (zh) * 2022-05-30 2025-04-11 丹麥商西蘭製藥公司 澱粉素類似物之液體調配物
WO2024022465A1 (fr) * 2022-07-29 2024-02-01 杭州九源基因工程有限公司 Dérivé polypeptidique d'amyline humaine et son utilisation
IL319599A (en) 2022-09-19 2025-05-01 Zealand Pharma As Combination therapy
TW202504913A (zh) 2023-06-21 2025-02-01 丹麥商西蘭製藥公司 減重
MX2025015167A (es) 2023-06-21 2026-02-03 Zealand Pharma As Analogos con propiedades mejoradas
TW202517291A (zh) 2023-06-30 2025-05-01 丹麥商西蘭製藥公司 組合療法
WO2025120002A1 (fr) 2023-12-04 2025-06-12 Zealand Pharma A/S Pétrélintide pour réduire le poids tout en préservant la masse maigre
TW202530247A (zh) 2023-12-04 2025-08-01 丹麥商西蘭製藥公司 方法
TW202545982A (zh) * 2024-02-07 2025-12-01 大陸商江蘇恆瑞醫藥股份有限公司 胰島澱粉樣多肽類似物及其醫藥用途
WO2025242620A1 (fr) 2024-05-20 2025-11-27 Medimmune Limited Combinaisons polypeptidiques et leurs utilisations
WO2025262301A1 (fr) 2024-06-20 2025-12-26 Zealand Pharma A/S Pétrélintide destiné à être utilisé dans le traitement de l'obésité, du diabète ou d'une maladie liée à l'obésité ou au diabète, ou dans le cadre de la réduction du poids corporel, de l'inhibition du gain de poids ou de la réduction de l'apport alimentaire
WO2026046286A1 (fr) * 2024-08-29 2026-03-05 杭州九源基因生物医药股份有限公司 Analogue d'amyline humaine, dérivé et utilisation médicale de celui-ci
WO2026058194A1 (fr) 2024-09-12 2026-03-19 Medimmune Limited Schémas posologiques de polypeptides
CN119161446B (zh) * 2024-11-22 2025-02-14 杭州诺泰诺和生物医药科技有限公司 胰淀素类似物的制备方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
WO1992015317A1 (fr) 1991-03-08 1992-09-17 Amylin Pharmaceuticals, Inc. Preparation synthetique d'amyline et d'analogues d'amyline
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
CA2100745C (fr) 1991-11-19 2007-07-31 Laura S. L. Gaeta Peptides agonistes de l'amyline et leur utilisation
CZ69596A3 (en) 1993-09-07 1997-06-11 Amylin Pharmaceuticals Inc Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
AU723268B2 (en) 1996-09-09 2000-08-24 Zealand Pharma A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
US5677279A (en) 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
CA2206028C (fr) 1997-06-04 2006-10-03 Frantisek Ziak Plate-forme pour exercices d'equilibre
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
WO1999034764A2 (fr) * 1998-01-09 1999-07-15 Amylin Pharmaceuticals, Inc. Compositions pharmaceutiques a agoniste d'amyline, contenant de l'insuline
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
CZ20013018A3 (cs) 1999-03-17 2002-02-13 Novo Nordisk A/S Způsob pro acylování aminoskupiny peptidu nebo proteinu a sloučenina
EP1631308B1 (fr) 2003-05-30 2013-07-31 Amylin Pharmaceuticals, LLC Nouveaux procedes et nouvelles compositions pour une administration amelioree par voie muqueuse de peptides et de proteines
NZ579621A (en) 2004-02-11 2011-03-31 Amylin Pharmaceuticals Inc Hybrid polypeptides with selectable properties
ATE471340T1 (de) * 2004-02-11 2010-07-15 Amylin Pharmaceuticals Inc Peptide der amylin familie, verfahren zu deren herstellung und verwendung
DE102004051014A1 (de) 2004-10-20 2006-04-27 Rwth Aachen Chemisch modifizierte Peptidanaloga
WO2007022123A2 (fr) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Polypeptides hybrides presentant des proprietes selectionnables
JP5252435B2 (ja) 2006-03-15 2013-07-31 ノボ・ノルデイスク・エー／エス アミリン誘導体
CA2677932A1 (fr) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Co-agonistes des recepteurs du glucagon/glp-1
EP2158214B1 (fr) 2007-06-15 2011-08-17 Zealand Pharma A/S Analogues du glucagon
EP2036539A1 (fr) 2007-09-11 2009-03-18 Novo Nordisk A/S Formulations stables d'amyline et ses analogues
EP2036923A1 (fr) 2007-09-11 2009-03-18 Novo Nordisk A/S Dérivés d'amyline améliorés
ES2662501T3 (es) 2008-10-21 2018-04-06 Novo Nordisk A/S Derivados de amilina
EP2370462B1 (fr) 2008-12-15 2014-07-16 Zealand Pharma A/S Analogues du glucagon
CN102282167B (zh) 2008-12-15 2014-08-13 西兰制药公司 胰高血糖素类似物
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
ES2477880T3 (es) 2008-12-15 2014-07-18 Zealand Pharma A/S Análogos del glucagón
WO2010107874A2 (fr) 2009-03-17 2010-09-23 Amylin Pharmaceuticals, Inc. Méthodes permettant d'agir sur la composition du corps au moyen d'agonistes d'amyline
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
ES2550761T3 (es) 2009-11-25 2015-11-12 Novo Nordisk A/S Método para producción de polipéptidos
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
US9169310B2 (en) 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
JP6121992B2 (ja) 2011-06-10 2017-04-26 ノヴォ ノルディスク アー／エス ポリペプチド
IN2014CN04401A (fr) 2011-12-23 2015-09-04 Zealand Pharma As
ES2640285T3 (es) 2012-04-19 2017-11-02 Novo Nordisk A/S Análogos de amilina humana
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
BR102013017626A2 (pt) 2013-06-14 2015-02-10 Univ Rio De Janeiro Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
JP2016208556A (ja) 2013-10-03 2016-12-08 三菱電機株式会社 デマンド予測装置及びデマンド予測方法
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
PL3057984T3 (pl) 2013-10-17 2018-12-31 Zealand Pharma A/S Acylowane analogi glukagonu
TW201625605A (zh) 2014-04-04 2016-07-16 賽諾菲公司 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類
CA2947587C (fr) 2014-05-02 2022-10-18 The Research Foundation For The State University Of New York Polypeptides a ilots amyloides presentant une solubilite amelioree
WO2016034604A1 (fr) 2014-09-04 2016-03-10 Novo Nordisk A/S Nouvel agoniste du récepteur de l'amyline et de la calcitonine
MA41202A (fr) 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
BR112017019378A2 (pt) * 2015-03-18 2019-02-19 Zealand Pharma A/S análogos de amilina
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
WO2018144671A1 (fr) 2017-02-01 2018-08-09 The Research Foundation For The State University Of New York Polypeptides à îlots amyloïdes mutants présentant une solubilité améliorée et leurs procédés d'utilisation

Also Published As

Publication number Publication date
US20180071366A1 (en) 2018-03-15
US11382956B2 (en) 2022-07-12
MY197024A (en) 2023-05-22
JP7064103B2 (ja) 2022-05-10
EP4736945A2 (fr) 2026-05-06
TWI784968B (zh) 2022-12-01
SA519401239B1 (ar) 2023-07-09
EP4074729B1 (fr) 2026-04-15
DK3510044T3 (da) 2021-12-13
EP4074729A1 (fr) 2022-10-19
ES2901386T3 (es) 2022-03-22
US10071140B2 (en) 2018-09-11
UA123369C2 (uk) 2021-03-24
US20200188485A1 (en) 2020-06-18
EP3510044A1 (fr) 2019-07-17
KR102498393B1 (ko) 2023-02-13
PE20190963A1 (es) 2019-07-08
SG11201901423XA (en) 2019-03-28
EP3510044B1 (fr) 2021-11-24
CN109863168B (zh) 2023-04-18
EP4736946A2 (fr) 2026-05-06
ZA201901253B (en) 2022-10-26
KR20190045333A (ko) 2019-05-02
IL264864B1 (en) 2023-06-01
AU2017322277A1 (en) 2019-03-28
PE20241305A1 (es) 2024-06-24
BR112019004534A2 (pt) 2019-06-25
WO2018046719A1 (fr) 2018-03-15
CN109863168A (zh) 2019-06-07
TW201811818A (zh) 2018-04-01
MX2019002599A (es) 2019-09-18
EA201990360A1 (ru) 2019-09-30
PH12019500474B1 (en) 2023-12-06
PH12019500474A1 (en) 2019-08-05
IL264864A (fr) 2019-04-30
AU2017322277B2 (en) 2021-11-11
US20210346468A1 (en) 2021-11-11
AR109514A1 (es) 2018-12-19
JP2019534248A (ja) 2019-11-28
US12083164B2 (en) 2024-09-10
IL264864B2 (en) 2023-10-01
NZ751286A (en) 2024-05-31
CA3035958A1 (fr) 2018-03-15
US20250064895A1 (en) 2025-02-27
CL2019000575A1 (es) 2019-05-10
CO2019002159A2 (es) 2019-07-31
US20190134159A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
MA46180A (fr) Analogues de l'amyline
MA42036A (fr) Analogues nucléosidiques 5'-substitués
IL257279A (en) Stable anti-ifnar1 formulation
EP3430731A4 (fr) Architecture d'iugw
IL264143B (en) Processes for preparing olaparib
EP3509581A4 (fr) Formulations de (r
FR3036037B1 (fr) Harnais d'encordement perfectionne
EP3443094A4 (fr) Procédés de réduction de l'expression de c9orf72
PT3645518T (pt) Síntese de omecamtiv mecarbil
EP3250367A4 (fr) Étalonnage d'agent
EP3406336A4 (fr) Nanofeuille de type structure c ur-écorce
EP3347334A4 (fr) Déshydrohalogénation d'hydrochlorofluorocarbones
EP3378606A4 (fr) Combinaison d'assistance
EP3710462A4 (fr) Analogues de brartémicine
IL282114A (en) Processes for preparing functionalized cyclooctenes
EP3482698A4 (fr) Instrument d'hémostase
EP3506254A4 (fr) Structure d'insonorisation
EP3426159A4 (fr) Identification de structures anatomiques
EP3500898A4 (fr) Hélage d'un véhicule
EP3431808A4 (fr) Butée d'arrêt
EP3407974A4 (fr) Analogues d'amlexanox
MA42690A (fr) Micropropagation d'un dattier abada
SI3512495T1 (sl) Formulacije prostaciklinskih analogov
EP3344280A4 (fr) Formation d'os
MA43764A (fr) Inhibiteur monovalent de l'interaction hutnfr1